Search research articles
Contact Us
Filters
Showing results (1-10 of 5,628) with videos related to
Page
of 563
Sort By:
Cancers
|
March 25, 2022
Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma
Landon L Chan, Stephen L Chan
The Lancet. Oncology
|
December 1, 2023
Drug development for hepatocellular carcinoma
Landon L Chan, Stephen L Chan
Journal of Hepatology
|
December 21, 2025
What's next after the 2025 BCLC update?
Landon L Chan, Stephen L Chan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 2, 2026
Transarterial Chemoembolization and Immunotherapy: Another Good Marriage?
Landon L Chan, Stephen L Chan
Liver International : Official Journal of the International Association for the Study of the Liver
|
January 21, 2023
The combination of ALBI and AFP response: A small step forward in HCC
Landon L Chan, Stephen L Chan
Clinical and Molecular Hepatology
|
March 12, 2023
The prime time for management of hepatocellular carcinoma in Hong Kong
Landon L Chan, Stephen L Chan
Therapeutic Advances in Medical Oncology
|
March 27, 2025
Future perspectives on immunotherapy for hepatocellular carcinoma
Landon L Chan, Stephen L Chan
Expert Opinion on Emerging Drugs
|
March 16, 2021
Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma
Landon L Chan, Stephen L Chan
Clinical and Molecular Hepatology
|
May 25, 2023
The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
Landon L Chan, Stephen L Chan
Biochimie
|
January 1, 1995
Apolipoprotein B messenger RNA editing: an update
L Chan
Page
of 563
Search research articles
Search
Showing results (1-10 of 5,628) with videos related to
Sort By:
Page
of 563
Cancers
|
March 25, 2022
Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma
Landon L Chan, Stephen L Chan
The Lancet. Oncology
|
December 1, 2023
Drug development for hepatocellular carcinoma
Landon L Chan, Stephen L Chan
Journal of Hepatology
|
December 21, 2025
What's next after the 2025 BCLC update?
Landon L Chan, Stephen L Chan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 2, 2026
Transarterial Chemoembolization and Immunotherapy: Another Good Marriage?
Landon L Chan, Stephen L Chan
Liver International : Official Journal of the International Association for the Study of the Liver
|
January 21, 2023
The combination of ALBI and AFP response: A small step forward in HCC
Landon L Chan, Stephen L Chan
Clinical and Molecular Hepatology
|
March 12, 2023
The prime time for management of hepatocellular carcinoma in Hong Kong
Landon L Chan, Stephen L Chan
Therapeutic Advances in Medical Oncology
|
March 27, 2025
Future perspectives on immunotherapy for hepatocellular carcinoma
Landon L Chan, Stephen L Chan
Expert Opinion on Emerging Drugs
|
March 16, 2021
Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma
Landon L Chan, Stephen L Chan
Clinical and Molecular Hepatology
|
May 25, 2023
The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
Landon L Chan, Stephen L Chan
Biochimie
|
January 1, 1995
Apolipoprotein B messenger RNA editing: an update
L Chan
Page
of 563